Litigation Details for Boston Heart Diagnostics Corporation v. MD Labs, Inc. (D. Conn. 2017)
✉ Email this page to a colleague
Boston Heart Diagnostics Corporation v. MD Labs, Inc. (D. Conn. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-08-01 |
| Court | District Court, D. Connecticut | Date Terminated | 2017-12-18 |
| Cause | 35:271 Patent Infringement | Assigned To | Michael Peter Shea |
| Jury Demand | Plaintiff | Referred To | |
| Parties | BOSTON HEART DIAGNOSTICS CORPORATION | ||
| Patents | 8,455,194 | ||
| Attorneys | Mark S. Baldwin | ||
| Firms | Brown Rudnick LLP | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Boston Heart Diagnostics Corporation v. MD Labs, Inc.
The biologic drug covered by the patent cited in this case is ⤷ Try a Trial .
Details for Boston Heart Diagnostics Corporation v. MD Labs, Inc. (D. Conn. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-08-01 | 1 | UNITED STATES PATENT NO 8,455,194 9. BHDX is a heart health … On or about June 4, 2013, United States Patent No. 8,455,194, which embodies diagnostic methods for … This is an action for patent infringement arising under the Patent Laws of the United States, …myopathy (the “’194 Patent”), was duly and legally issued by the United Stated Patent and Trademark Office…copy of the ’194 Patent is attached hereto as Exhibit A. 11. The ’194 Patent is owned by Isis | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
